Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Fuji
QuintilesIMS
Federal Trade Commission
Johnson and Johnson
Healthtrust
Harvard Business School
Chubb
Merck
Medtronic

Generated: February 19, 2018

DrugPatentWatch Database Preview

VESICARE Drug Profile

« Back to Dashboard

Which patents cover Vesicare, and when can generic versions of Vesicare launch?

Vesicare is a drug marketed by Astellas and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty-two patent family members in twenty-two countries.

The generic ingredient in VESICARE is solifenacin succinate. There are thirty drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the solifenacin succinate profile page.
Summary for VESICARE
International Patents:32
US Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: 5
Bulk Api Vendors: 81
Clinical Trials: 47
Patent Applications: 1,090
Drug Prices:see details
DailyMed Link:VESICARE at DailyMed
Drug patent expirations by year for VESICARE
Pharmacology for VESICARE
Medical Subject Heading (MeSH) Categories for VESICARE

US Patents and Regulatory Information for VESICARE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astellas VESICARE solifenacin succinate TABLET;ORAL 021518-001 Nov 19, 2004 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Astellas VESICARE solifenacin succinate TABLET;ORAL 021518-002 Nov 19, 2004 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for VESICARE
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Tablets 5 mg and 10 mg ➤ Subscribe 4/8/2009

Non-Orange Book US Patents for VESICARE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,174,896 Quinuclidine derivatives and medicinal composition thereof ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for VESICARE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
133 Luxembourg ➤ Sign Up 91133, EXPIRES: 20181118
C0032 France ➤ Sign Up PRODUCT NAME: SUCCINATE DE SOLIFENACINE; NAT. REGISTRATION NO/DATE: NL 30 109 20040816; FIRST REGISTRATION: NL - RVG 29 151 20031216
2004 00037 Denmark ➤ Sign Up
C014/2004 Ireland ➤ Sign Up SPC014/2004: 20050803, EXPIRES: 20181215
0801067/01 Switzerland ➤ Sign Up PRODUCT NAME: SOLIFENACIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 57203 12.05.2006
C/GB04/029 United Kingdom ➤ Sign Up PRODUCT NAME: SOLIFENACIN AND/OR PHARMACEUTICALLY ACTIVE SALT THEREOF; REGISTERED: NL RVG 29151 20031216; NL RVG 29152 20031216; UK PL 00166/0197 20040816; UK PL 0016/0198 20040816
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Citi
Cerilliant
Colorcon
Cipla
US Army
Deloitte
Teva
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot